1. Fauser BC, Tarlatzis BC, Rebar RW, et al. Consensus on women’s healthaspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril.2012;97(1):28-38.
2. Revised 2003 consensus on diagnostic criteria and long-term healthrisks related to polycystic ovary syndrome (PCOS). Hum Reprod.2004;19(1):41-47.
3. Siddiqui S, Mateen S, Ahmad R, Moin S. A brief insight into theetiology, genetics, and immunology of polycystic ovarian syndrome(PCOS). J Assist Reprod Genet. 2022 Oct 3.
4. Patel S. Polycystic ovary syndrome (PCOS), an inflammatory, systemic,lifestyle endocrinopathy. J Steroid Biochem Mol Biol. 2018;182:27-36.
5. Singh S, Pal N, Shubham S, Sarma DK, Verma V, Marotta F, Kumar M.Polycystic ovary syndrome: etiology, current management, and futuretherapeutics. J Clin Med . 2023;12(4):1454.
6. McAllister JM, Legro RS, Modi BP, Strauss JF. Functional genomics ofPCOS: from GWAS to molecular mechanisms. Trends Endocrinol AmpMetab. 2015;26(3):118-24.
7. Saadia Z. Follicle stimulating hormone (LH: FSH) ratio in polycysticovary syndrome (PCOS) - obese vs. non- obese women. Med Arch.2020;74(4):289.
8. Palaniappan M, Menon KM. Luteinizing hormone/human chorionicgonadotropin-mediated activation of mtorc1 signaling is requiredfor androgen synthesis by theca-interstitial cells. Mol Endocrinol.2012;26(10):1732-1742.
9. Yildiz BO, Azziz R. The adrenal and polycystic ovary syndrome. RevEndocr Metab Disord. 2007;8(4):331-342.
10. Fridlyand LE, Philipson LH. Reactive species and early manifestationof insulin resistance in type 2 diabetes. Diabetes Obes Metab. 2006Mar;8(2):136-45.
11. Dunaif A, Xia J, Book CB, Schenker E, Tang Z. Excessive insulinreceptor serine phosphorylation in cultured fibroblasts and in skeletalmuscle. A potential mechanism for insulin resistance in the polycysticovary syndrome. J Clin Investig. 1995;96(2):801-810.
12. Chen L, Xu WM, Zhang D. Association of abdominal obesity, insulinresistance, and oxidative stress in adipose tissue in women with polycysticovary syndrome. Fertil Steril. 2014;102(4):1167-1174.
13. Moghetti P, Tosi F, Bonin C, et al. Divergences in insulin resistancebetween the different phenotypes of the polycystic ovary syndrome. JClin Endocrinol Amp Metab. 2013;98(4):E628-E637.
14. Zangeneh FZ, Naghizadeh MM, Masoumi M. Polycystic ovarysyndrome and circulating inflammatory markers. Int J Reprod Biomed.2017;15(6):375-382.
15. Armanini D, Boscaro M, Bordin L, Sabbadin C. Controversies inthe pathogenesis, diagnosis and treatment of PCOS: focus on insulinresistance, inflammation, and hyperandrogenism. Int J Mol Sci.2022 8;23(8):4110.
16. Diamanti-Kandarakis E. Polycystic ovarian syndrome: pathophysiology,molecular aspects and clinical implications. Expert Rev Mol Med.2008;10:e3.
17. Mannera§s-Holm L, Leonhardt H, Kullberg, et al. Adipose tissue hasaberrant morphology and function in PCOS: enlarged adipocytes andlow serum adiponectin, but not circulating sex steroids, are stronglyassociated with insulin resistance. Endocrinology. 2011;152(1):332.
18. Azziz R, Carmina E, Chen Z, et al. Polycystic ovary syndrome. Nat RevDis Primers. 2016;2(1):1-18.
19. Sivanandy MS, Ha SK. The role of serum anti-mullerian hormonemeasurement in the diagnosis of polycystic ovary syndrome.Diagnostics. 2023;13(5):907.
20. Wang J, Yin T, Liu S. Dysregulation of immune response in PCOSorgan system. Front Immunol. 2023;14:1169232.
21. Witchel SF, Burghard AC, Tao RH, Oberfield SE. The diagnosis andtreatment of PCOS in adolescents. Curr Opin Pediatr . 2019;31(4):562-569.
22. Dokuzeylül Güngör N, Güngör K, Yurci A, Cil K, Hatırnaz Ş. Ovariandrilling down-regulates endometrial nuclear factor-κB p65 expressionin women with PCOS: A prospective case-control study. Turk J ObstetGynecol. 2022;19(1):45-50.
23. Diamanti-Kandarakis E, Dunaif A. Insulin resistance and thepolycystic ovary syndrome revisited: an update on mechanisms andimplications. Endocr Rev. 2012;33(6):981-1030.
24. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, TaylorAE, Witchel SF. The Androgen Excess and PCOS Society criteria for thepolycystic ovary syndrome: the complete task force report. Fertil Steril.2009;91(2):456-488.
25. Rudnicka E, Kunicki M, Calik-Ksepka A, Suchta K, DuszewskaA, Smolarczyk K, Smolarczyk R. Anti-Müllerian hormone inpathogenesis, diagnostic and treatment of PCOS. Int J Mol Sci . 2021Nov 19;22(22):12507.
26. Teede HJ, Joham AE, Paul E, Moran LJ, Loxton D, Jolley D, LombardC. Longitudinal weight gain in women identified With polycystic ovarysyndrome: results of an observational study in young women. Obesity.2013;21(8):1526-32.
27. Álvarez-Blasco F, Botella-Carretero JI, San Millán JL, Escobar-Morreale HF. Prevalence and characteristics of the polycystic ovarysyndrome in overweight and obese women. Arch Intern Med. 2006 Oct23;166(19):2081.
28. Koivuaho E, Laru J, Ojaniemi M, et al. Age at adiposity reboundin childhood is associated with PCOS diagnosis and obesity inadulthood—longitudinal analysis of BMI data from birth to age 46 incases of PCOS. Int J Obes. 2019;43(7):1370-1379.
29. Shang K, Jia X, Qiao J, Kang J, Guan Y. Endometrial abnormality inwomen with polycystic ovary syndrome. Reprod Sci. 2012;19(7):674-83.
30. Gürbüz T, Dokuzeylül Güngör N, Yurci A. Does intracytoplasmic sperminjection and the risk of gestational diabetes in patients with polycysticovarian syndrome? Anatolian Curr Med J. 2021;3(1);53-58.
31. Stefanaki C, Bacopoulou F, Livadas S, et al. Impact of a mindfulnessstress management program on stress, anxiety, depression and qualityof life in women with polycystic ovary syndrome: a randomizedcontrolled trial. Stress. 2014;18(1):57-66.
32. Stein IF, Leventhal ML. Amenorrhea associated with bilateralpolycystic ovaries. Am J Obstet Gynecol. 1935;29(2):181-91.
33. Zawadski J. Diagnostic criteria for polycystic ovary syndrome: towardsa rational approach. In: Polycystic ovary syndrome. Boston, MA, USA:Blackwell Scientific; 1992.
34. Bozdag G, Mumusoglu S, Zengin D, Karabulut E, Yildiz BO. Theprevalence and phenotypic features of polycystic ovary syndrome: asystematic review and meta-analysis. Hum Reprod. 2016;31(12):2841-2855.
35. Pundir C, Deswal R, Narwal V, Dang A. The prevalence of polycysticovary syndrome: a brief systematic review. J Hum Reprod Sci .2020;13(4):261.
36. Azziz R, Carmina E, Dewailly D, et al. Criteria for defining polycysticovary syndrome as a predominantly hyperandrogenic syndrome:an androgen excess society guideline. J Clin Endocrinol Amp Metab .2006;91(11):4237-4245.
37. Teede HJ, Misso ML, Costello MF, et al. Recommendations fromthe international evidence-based guideline for the assessmentand management of polycystic ovary syndrome. Clin Endocrinol .2018;89(3):251-68.
38. Hoeger KM, Dokras A, Piltonen T. Update on PCOS: consequences,challenges, and guiding treatment. J Clin Endocrinol Metab .2021;106(3):e1071-e1083.
39. de Medeiros SF. Risks, benefits size and clinical implications ofcombined oral contraceptive use in women with polycystic ovarysyndrome. Reprod Biol Endocrinol. 2017;15(1):1-17.
40. Morley LC, Tang T, Yasmin E, Norman RJ, Balen AH. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoeaand subfertility. Cochrane Database Syst Rev. 2017;11:CD003053-CD003053.
41. Yurci A, Dokuzeylül Güngör N, Güngör K, Hatırnaz Ş. Correlationof serum leptin and ghrelin levels with endocrine and reproductiveparameters in women with clomiphene citrate resistant polycysticovary syndrome. Turk J Obstet Gynecol. 2022;19(2):124-129
42. Gungor ND, Gurbuz T, Onal M. Comparison of complication ratesafter transvaginal ultrasound-guided oocyte pick-up procedures withrespect to ovarian response. Clin Exp Reprod Med. 2022 Jun;49(2):142-148